Cytokine expression in lupus kidneys

Lupus

Volumn 14, Issue 1, 2005, Pages 13-18

  Aringer, M ^a   Smolen, J S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Fibrosis; Glomerulonephritis; Inflammation; Lupus; Renal cytokines

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; CYTOKINE PRODUCTION; GLOMERULONEPHRITIS; IMMUNOREGULATION; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL;

ANIMALS; CYTOKINES; HUMANS; INTERFERON TYPE II; INTERLEUKINS; LUPUS NEPHRITIS; MICE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13444266045     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2053oa     Document Type: Review

References (64)

1. Lauwerys BR, Houssiau FA. Cytokines: clues to the pathogenesis of SLE. Lupus 1998; 7: 211-213.
2. Theofilopoulos AN, Lawson BR. Tumour necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999; 58(suppl. 1): 49-55.
3. Aringer M, Smolen JS. Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 172-177.
4. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000; 99: 352-360.
5. Debets JM, Van der Linden CJ, Dieteren IE, Leeuwenberg JF, Buurman WA. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol 1988; 141: 1197-1201.
6. Takemura T, Yoshioka K, Murakami K, et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 1994; 424: 459-464.
7. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995; 26: 558-564.
8. Neale TJ, Ruger BM, Macaulay H et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995; 146: 1444-1454.
9. Nakajima M, Kawahara S, Sakagami Y, et al. Immunogold labelling of cytokines in glomeruli in children with various renal diseases. Nephron 1999; 83: 132-138.
10. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 1998; 7: 154-158.
11. Aringer M, Zimmermann C, Graninger WB et al. TNF is an essential mediator in lupus nephritis. Arthritis Rheum 2002; 46: 3418-3419 (Abstract).
12. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988; 141: 3050-3054.
13. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143: 3470-3475.
14. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995; 47: 122-130.
15. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146-150.
16. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-1074.
17. Gabay C, Cakir N, Moral F et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-308.
18. Aringer M, Stummvoll GH, Steiner G et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 876-881.
19. Schlondorff D. Roles of the mesangium in glomerular function. Kidney Int 1996; 49: 1583-1585.
20. Moore KJ, Yeh K, Naito T, Kelley VR. TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J Immunol 1996; 157: 427-432.
21. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of TNFα blockade in systemic lupus erythematosus - an open label study. Arthritis Rheum 2004; 50: 3161-3169.
22. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline. Lupus 2001; 10: 23-31.
23. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4(suppl. 3): S233-S242.
24. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-196.
25. Fukatsu A, Matsuo S, Tamai H, Sakamoto N, Matsuda T, Hirano T. Distribution of interleukin-6 in normal and diseased human kidney. Lab Invest 1991; 65: 61-66.
26. Horii Y, Iwano M, Hirata E et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int 1993; 39: S71-S75.
27. Ruef C, Budde K, Lacy J et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 1990; 38: 249-257.
28. Moutabarrik A, Nakanishi I, Ishibashi M. Interleukin-6 and interleukin-6 receptor are expressed by cultured glomerular epithelial cells. Scand J Immunol 1994; 40: 181-186.
29. Kiberd BA. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 1993; 4: 58-61.
30. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 1994; 144: 927-937.
31. Choy EH, Isenberg DA, Garrood T et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-3150.
32. Brennan FM. A follow-up to 'Anti-cytokine therapy in chronic destructive arthritis' by Wim B van den Berg. Arthritis Res 2001; 3: 211-213.
33. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003; 48: 3308-3319.
34. Boswell JM, Yui MA, Endres S, Burt DW, Kelley VE. Novel and enhanced IL-1 gene expression in autoimmune mice with lupus. J Immunol 1988; 141: 118-124.
35. Lemay S, Mao C, Singh AK. Cytokine gene expression in the MRL/lpr model of lupus nephritis. Kidney Int 1996; 50: 85-93.
36. Faust J, Menke J, Kriegsmann J et al. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum 2002; 46: 3083-3095.
37. Kiberd BA, Stadnyk AW. Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology 1995; 30: 131-137.
38. Schorlemmer HU, Kanzy EJ, Langner KD, Kurrle R. Immunoregulation of SLE-like disease by the IL-1 receptor: disease modifying activity on BDF1 hybrid mice and MRL autoimmune mice. Agents Actions 1993; 39: C117-C120.
39. Bossu P, Neumann D, Del Giudice E et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 2003; 100: 14181-14186.
40. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
41. Masutani K, Akahoshi M, Tsuruya K et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097-2106.
42. Uhm WS, Na K, Song GW et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003; 42: 935-938.
43. Husby G, Williams RC, Jr., Ramirez F, Tung KS. Absence of interferons-alpha and -gamma in renal lesions of systemic lupus erythematosus and membranous glomerulonephritis. Clin Immunol Immunopathol 1986; 39: 68-80.
44. Murata H, Matsumura R, Koyama A et al. T cell receptor repertoire of T cells in the kidneys of patients with lupus nephritis. Arthritis Rheum 2002; 46: 2141-2147.
45. Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995; 25: 6-12.
46. Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol 1998; 161: 494-503.
47. Carvalho-Pinto CE, Garcia MI, Mellado M et al. Autocrine production of IFN-gamma by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J Immunol 2002; 169: 1058-1067.
48. Okada H, Konishi K, Nakazato Y et al. Interleukin-4 expression in mesangial proliferative glomerulonephritis. Am J Kidney Dis 1994; 23: 242-246.
49. Furusu A, Miyazaki M, Koji T et al. Involvement of IL-4 in human glomerulonephritis: an in situ hybridization study of IL-4 mRNA and IL-4 receptor mRNA. J Am Soc Nephrol 1997; 8: 730-741.
50. Nakazato Y, Okada H, Tajima S et al. Interleukin-4 modulates collagen synthesis by human mesangial cells in a type-specific manner. Am J Physiol 1996; 270: F447-F453.
51. Ruger BM, Erb KJ, He Y, Lane JM, Davis PF, Hasan Q. Interleukin-4 transgenic mice develop glomerulosclerosis independent of immunoglobulin deposition. Eur J Immunol 2000; 30: 2698-2703.
52. Nakazato Y, Hayashida T, Kanno Y et al. Interleukin (IL)-1 and IL-4 synergistically stimulate NF-IL6 activity and IL-6 production in human mesangial cells. Kidney Int 1998; 54: 71-79.
53. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-310.
54. Kalechman Y, Gafter U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J Immunol 1997; 159: 2658-2667.
55. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
56. Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. Arthritis Rheum 2000; 43: 1976-1981.
57. Chen W, Wahl SM. TGF-beta: the missing link in CD4+ CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003; 14: 85-89.
58. Iwano M, Akai Y, Fujii Y, Dohi Y, Matsumura N, Dohi K. Intraglomerular expression of transforming growth factor-beta 1 (TGF-beta 1) mRNA in patients with glomerulonephritis: quantitative analysis by competitive polymerase chain reaction. Clin Exp Immunol 1994; 97: 309-314.
59. Yamamoto T, Noble NA, Cohen AH et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-469.
60. Raz E, Dudler J, Lotz M et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292.
61. Grande JP. Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 1998; 7: 604-610.
62. Aringer M, Smolen JS. TNF and other proinflammatory cytokines in SLE: a rationale for therapeutic intervention. Lupus 2004; in press.
63. Sekikawa T, Kashihara N, Maruyama K et al. Expression of interleukin-8 in human glomerulonephritis. Res Commun Mol Pathol Pharmacol 1998; 99: 217-224.
64. Kiberd BA, Young ID. Modulation of glomerular structure and function in murine lupus nephritis by methylprednisolone and cyclophosphamide. J Lab Clin Med 1994; 124: 496-506.